Immunomedics, Inc. Company Profile

12:15 EDT 22nd March 2019 | BioPortfolio

Immunomedics (the “Company”) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of eight clinical-stage product candidates. Immunomedics’ portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxicities that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics’ most advanced ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. IMMU-132 has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least two prior therapies for metastatic disease. Immunomedics has a research collaboration with Bayer to study epratuzumab as a thorium-227-labeled antibody. Immunomedics has other ongoing collaborations in oncology with independent cancer study groups. The IntreALL Inter-European study group is conducting a large, randomized Phase 3 trial combining epratuzumab with chemotherapy in children with relapsed acute lymphoblastic leukemia at clinical sites in Australia, Europe, and Israel. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and preclinical development. These include combination therapies involving its antibody-drug conjugates, bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 310 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. For additional information on the Company, please visit its website at The information on its website does not, however, form a part of this press release.

News Articles [65 Associated News Articles listed on BioPortfolio]

Immunomedics CEO Michael Pehl Resigns

Michael Pehl has resigned as CEO of Immunomedics (NASDAQ: IMMU), 15 months after he left Celgene (NASDAQ: CELG) to take the top job at the Morris Plains, NJ, company. In a press release, Immunomedics ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunomedics Inc. - IMMU

NEW YORK, Dec. 21, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immunomedics Inc. ("Immunomedics" or the "Company") (NASDAQ: IMMU). Such investors are advis...

Johnson Matthey, Immunomedics Partner for Cancer

Strategic manufacturing partnership is for the large-scale production of the drug-linker used in Immunomedics’ lead antibody-drug conjugate

Immunomedics Receives CRL from FDA for Sacituzumab Govitecan BLA Seeking Accelerated Approval for Treatment of Metastatic TNBC

MORRIS PLAINS, N.J., Jan. 17, 2019 (GLOBE NEWSWIRE) — Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody...

FDA observes manipulation of data at Immunomedics facility

Following the US FDA issuing a CRL to Immunomedics, the agency has revealed its inspection found instances of data integrity breaches and manipulation.

Amidst FDA Rejection, Immunomedics' CEO and President Steps Down

In addition to its fourth-quarter financial report, Morris Plains, NJ-based Immunomedics announced that its president, chief executive officer and board member, Michael Pehl, was stepping down for per...

FDA rejects Immunomedics breast cancer drug, extending long regulatory drought

Immunomedics' antibody drug conjugate to treat women with an aggressive form of breast cancer could not be approved at this time, the FDA said.

Not Again: FDA Issues CRL for Immunomedics' Breast Cancer Treatment

Immunomedics was hoping for a green light from the U.S. Food and Administration for its triple-negative breast cancer treatment, sacituzumab govitecan. However, this morning the company announced that...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

Immunomedics, Inc.

Immunomedics (the “Company”) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune...


Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseas...

More Information about "Immunomedics, Inc." on BioPortfolio

We have published hundreds of Immunomedics, Inc. news stories on BioPortfolio along with dozens of Immunomedics, Inc. Clinical Trials and PubMed Articles about Immunomedics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immunomedics, Inc. Companies in our database. You can also find out about relevant Immunomedics, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Corporate Database Quicklinks

Searches Linking to this Company Record